查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1577408

亨廷顿舞蹈症药物市场：按类型、最终用户划分 - 全球预测 2025-2030

Huntington's Disease Therapeutics Market by Type (Disease-modifying Therapies, Gene Therapies, Medication), End-User (Hospitals, Long-Term Care Facilities, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年亨廷顿病治疗市值为5.1601亿美元，预计到2024年将达到5.9743亿美元，复合年增长率为17.14%，预计到2030年将达到15.6174亿美元。

亨丁顿舞蹈症药物包括多种旨在控制症状或减缓亨丁顿舞蹈症进展的治疗方法，亨丁顿舞蹈症是一种以脑神经细胞进行性退化为特征的遗传性疾病。需要这些药物是因为亨廷顿舞蹈症对患者的生活品质有重大影响，对家庭和医疗保健系统带来身体和经济负担，而且目前还没有既定的治疗方法。应用包括药物治疗、基因静默方法以及临床试验中的先进治疗，例如 CRISPR 和RNA干扰技术，这些技术已显示出改变疾病遗传轨迹的潜力。最终用途范围已显着扩展到医院、专科诊所和专注于神经退化性疾病的研究机构。

主要市场统计
基准年[2023] 51601万美元
预测年份 [2024] 5.9743 亿美元
预测年份 [2030] 15.6174亿美元
复合年增长率（%） 17.14%

市场成长受到研发资金增加、遗传和基因组科学进步以及创新候选药物不断增加的影响。最近的商机在于个人化医疗方法和跨产业合作，以加速新型疗法的开发和商业化。然而，它也存在局限性，包括复杂的监管环境、高昂的开发成本以及针对中枢神经系统的有效药物的固有挑战。由于这种疾病的罕见性和基因检测的伦理考虑，招募患者进行临床试验仍然很困难。

创新和研究的最佳领域包括改进更有效地穿过血脑障壁的药物输送系统、开发更精确的基因编辑工具以及增强用于早期诊断的生物标记。与科技公司合作利用人工智慧进行深度表型分析和药物发现具有巨大的潜力。市场仍然充满活力，重点是转化研究和跨学科方法的整合。相关人员应强调强有力的伙伴关係和以患者为中心的模式，以克服现有挑战并利用快速发展的亨廷顿病药物领域的新机会。

市场动态：揭示快速发展的亨廷顿病药物市场的关键市场洞察

供应和需求的动态交互作用正在改变亨廷顿氏症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 对抑制亨丁顿舞蹈症症状的药物的需求不断增加
    • 政府不断采取措施提高人们对亨丁顿舞蹈症的认识
  • 市场限制因素
    • 先进治疗相关的高成本
  • 市场机会
    • 增加临床研究活动以开发亨廷顿舞蹈症疗法
    • 亨丁顿舞蹈症患者的药物核准增加
  • 市场挑战
    • 亨廷顿舞蹈症疗法开发中与严格监管政策相关的问题

波特五力：驾驭亨丁顿舞蹈症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对亨丁顿舞蹈症药物市场的影响

外部宏观环境因素在塑造亨廷顿舞蹈症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解亨丁顿舞蹈症治疗药物市场的竞争状况

对亨廷顿舞蹈症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵亨丁顿舞蹈症治疗市场供应商的绩效评估

FPNV 定位矩阵是评估亨丁顿舞蹈症治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为亨丁顿舞蹈症药物市场的成功指明道路

对于希望加强在全球市场的影响力的公司来说，亨廷顿舞蹈症治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对抑制亨丁顿舞蹈症症状的药物的需求增加
      • 政府加强提高人们对亨丁顿舞蹈症的认识
    • 抑制因素
      • 与先进治疗相关的高成本
    • 机会
      • 扩大临床研究活动以开发亨廷顿氏舞蹈症的治疗药物
      • 亨丁顿舞蹈症患者的药物核准增加
    • 任务
      • 亨丁顿舞蹈症药物开发的严格监管政策相关议题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章亨廷顿氏症治疗药物市场：依类型

  • 疾病修正治疗
  • 基因治疗
  • 药物治疗
  • 职能治疗
  • 治疗

第七章亨廷顿氏症治疗药物市场：依最终使用者分类

  • 医院
  • 长期照护设施
  • 专科诊所

第八章 美洲亨廷顿病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区亨廷顿氏症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲亨廷顿舞蹈症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-69324464D29B

The Huntington's Disease Therapeutics Market was valued at USD 516.01 million in 2023, expected to reach USD 597.43 million in 2024, and is projected to grow at a CAGR of 17.14%, to USD 1,561.74 million by 2030.

Huntington's Disease Therapeutics encompass a range of treatments aimed at managing the symptoms or slowing the progression of Huntington's Disease, a genetic disorder characterized by the progressive degeneration of nerve cells in the brain. The necessity for these therapeutics arises from the absence of a cure for Huntington's, alongside the significant impact the disorder has on patients' quality of life and the physical and economic burden it imposes on families and healthcare systems. The application includes pharmacological treatments, gene-silencing approaches, and advanced therapies in clinical trials, such as CRISPR and RNA interference technologies, which showcase potential in altering the genetic trajectory of the disease. The end-use scope largely spans hospitals, specialty clinics, and research institutions focused on neurodegenerative disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 516.01 million
Estimated Year [2024] USD 597.43 million
Forecast Year [2030] USD 1,561.74 million
CAGR (%) 17.14%

Market growth is influenced by increasing funding for research and development, advances in genetic and genomic sciences, and a growing pipeline of innovative drug candidates. Recent opportunities lie in personalized medicine approaches and cross-industry partnerships to expedite novel therapeutics' development and distribution. However, limitations include the complex regulatory landscape, high costs of development, and the inherent challenges of targeting the central nervous system with effective drugs. Patient recruitment for clinical trials remains challenging due to the disease's rarity and ethical considerations surrounding genetic testing.

The best areas for innovation and research include improving drug delivery systems to cross the blood-brain barrier efficiently, developing more precise gene-editing tools, and enhancing biomarkers for early diagnosis. Collaboration with technology firms to leverage AI for deep phenotyping and drug discovery offers substantial potential. The market remains dynamic, with a strong emphasis on translational research and the integration of multidisciplinary approaches. Stakeholders should focus on robust partnerships and patient-centric models to overcome existing challenges and capitalize on emerging opportunities in the rapidly advancing landscape of Huntington's Disease therapeutics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Huntington's Disease Therapeutics Market

The Huntington's Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in need for drugs to control Huntington's disease symptoms
    • Rising government initiatives to increase awareness about Huntington's disease
  • Market Restraints
    • High cost associated with advanced treatments
  • Market Opportunities
    • Increase in clinical research activities for drug development for Huntington's disease
    • Growing drug approvals for the treatment of Huntington's disease patients
  • Market Challenges
    • Problems associated with strict regulatory policies for development of Huntington's disease drugs

Porter's Five Forces: A Strategic Tool for Navigating the Huntington's Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Huntington's Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Huntington's Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Huntington's Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Huntington's Disease Therapeutics Market

A detailed market share analysis in the Huntington's Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Huntington's Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Huntington's Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Huntington's Disease Therapeutics Market

A strategic analysis of the Huntington's Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Huntington's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Alterity Therapeutics Limited, Annexon Biosciences, AOP Orphan Pharmaceuticals GmbH, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals Inc., Ipsen S.A., Lupin Limited, Medesis Pharma SA, Mitochon Pharmaceuticals, Inc., NeuExcell Therapeutics Inc, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Prilenia Therapeutics B.V., PTC Therapeutics Inc., SOM Innovation Biotech S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., uniQure N.V., Vaccinex Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Huntington's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Disease-modifying Therapies, Gene Therapies, Medication, Occupational Therapies, and Symptomatic Treatment.
  • Based on End-User, market is studied across Hospitals, Long-Term Care Facilities, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in need for drugs to control Huntington's disease symptoms
      • 5.1.1.2. Rising government initiatives to increase awareness about Huntington's disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in clinical research activities for drug development for Huntington's disease
      • 5.1.3.2. Growing drug approvals for the treatment of Huntington's disease patients
    • 5.1.4. Challenges
      • 5.1.4.1. Problems associated with strict regulatory policies for development of Huntington's disease drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Huntington's Disease Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Disease-modifying Therapies
  • 6.3. Gene Therapies
  • 6.4. Medication
  • 6.5. Occupational Therapies
  • 6.6. Symptomatic Treatment

7. Huntington's Disease Therapeutics Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Long-Term Care Facilities
  • 7.4. Specialty Clinics

8. Americas Huntington's Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Huntington's Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Huntington's Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Alterity Therapeutics Limited
  • 3. Annexon Biosciences
  • 4. AOP Orphan Pharmaceuticals GmbH
  • 5. Bausch Health Companies Inc.
  • 6. Dr. Reddy's Laboratories Ltd.
  • 7. Hikma Pharmaceuticals PLC
  • 8. Ionis Pharmaceuticals Inc.
  • 9. Ipsen S.A.
  • 10. Lupin Limited
  • 11. Medesis Pharma SA
  • 12. Mitochon Pharmaceuticals, Inc.
  • 13. NeuExcell Therapeutics Inc
  • 14. Neurocrine Biosciences, Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Prilenia Therapeutics B.V.
  • 18. PTC Therapeutics Inc.
  • 19. SOM Innovation Biotech S.A.
  • 20. Sun Pharmaceutical Industries Limited
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. uniQure N.V.
  • 23. Vaccinex Inc.
  • 24. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. HUNTINGTON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HUNTINGTON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUNTINGTON'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE-MODIFYING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY OCCUPATIONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM HUNTINGTON'S DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. HUNTINGTON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. HUNTINGTON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023